All of the manuscripts should be prepared in strict observation of research and publication ethics guidelines recommended by the Council of Science Editors (http://www.councilscienceeditors.org/
), International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org/
), and World Association of Medical Editors (WAME, http://www.wame.org/
). Any study including human subjects or human data must be reviewed and approved by a responsible institutional review board(IRB). Please refer to the principles embodied in the Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3/index.html
) for all investigations involving human materials. Animal experiments also should be reviewed by an appropriate committee (IACUC) for the care and use of animals. Also studies with pathogens requiring a high degree of biosafety should pass review of a relevant committee (IBC). The editor of The Aesthetics may request submission of copies of informed consents from human subjects in clinical studies or IRB approval documents. The Aesthetics will Revised on August 16th 2015 (2nd Revision) Instructions to Authors follow the guidelines by the Committee on Publication Ethics (COPE, http://publicationethics.org/
) for settlement of any misconduct.
Authorship credit should be based on
- 1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work
- 2) Drafting the work or revising it critically for important intellectual content
- 3) Final approval of the version to be published
- 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Authors should meet conditions of 1, 2, 3, and 4. In addition, an author should be accountable for the parts of the work he or she has done and should be able to identify which co-authors are responsible for specific other parts of the work. Authors should have confidence in the integrity of the contributions of their coauthors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #s2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript.
When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
follows the recommendations for authorship by the ICMJE, 2013 (http://www.icmje.org/icmjerecommendations.pdf
) and Good Publication Practice Guidelines for Medical Journals 2nd Edition (Korean).
Conflict of Interest
The corresponding author of an article is asked to inform the Editor of the authors' potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest should be disclosed in the cover letter even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems. Disclosure form shall be same with ICMJE Uniform Disclosure Form for Potential Conflicts of Interest (http://www.icmje.org/coi_disclosure.pdf
). The Editor will decide whether the information on the conflict should be included in the published paper.
Redundant Publication and Plagiarism
Redundant publication is defined as "reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s)". Characteristics of reports that are substantially similar include the following: (a) "at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant publication)," (b) "the subject or study populations are often the same or similar," (c) "the methodology is typically identical or nearly so," and (d) "the results and their interpretation generally vary little, if at all."
When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other already published material or material being evaluated for publication and should also state how the manuscript submitted to International Medical Journal of Plastic Surgery, Aesthetics and Cosmetic Treatment differs substantially from this other material. If all or part of your patient population was previously reported, this should be mentioned in the Materials and Methods, with citation of the appropriate reference(s).
Redundant Publication and Plagiarism
Clinical trial defined as "any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome" should be registered to the primary registry to be prior publication. The Aesthetics
accepts the registration in any of the primary registries that participate in the WHO International Clinical Trials Portal (http://www.who.int/ictrp/en/
), NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/
), ISRCTN Resister (www.ISRCTN.org
), University Hospital Medical Information Network (www.umin.ac.jp/ctr/index/htm
), or Netherlands Trial Register (http://www.trialregister.nl/trialreg/index.asp
). The clinical trial registration number shall be published at the end of the abstract.